Molnupiravir India Licenses: Nuances, Local Data In Focus
Executive Summary
MSD-India Region chief outlines further specifics around the just-announced voluntary licensing deal for molnupiravir with Indian firms, noting an expectation to discuss local data needs with the country’s regulator. All eyes are also on whether non-licensee Natco will stay the course for its application for the investigational antiviral.
You may also be interested in...
Merck’s Molnupiravir Set To Lead Forecast $6bn COVID-19 Oral Antiviral Market
Merck’s antiviral could play a big role, but only if it proves effective in broader settings, such as post-exposure prophylaxis.
Merck’s Oral Antiviral Data In COVID-19 May Change Pandemic Outlook
Merck/Ridgeback’s ribonucleoside analog shows nearly 50% reduction of risk for hospitalization or death in Phase III study. Firms will seek EUA in US; a contract is in place for 1.7 million courses of therapy.
Big US Launch Promise For Cipla In FY23, Eyes On Peptide Filings
Cipla signals meaningful US launch line-up in fiscal 2023, which analysts anticipate could include generic versions of Advair, Revlimid and Abraxane. Partnered peptide injectable filings also bolster pipeline opportunities.